Related Experiment Video
Updated: Jun 25, 2026

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
[Promoter hypermethylation gene patterns in gynecological tumors]
Pamela Leal Rojas1, Leonardo Anabalón Rodríguez, Patricia García Muñoz
1Departamento de Anatomía Patológica, Laboratorio de Patología Molecular, Universidad de La Frontera, Temuco, Chile.
Background And Objective:
Gene silencing mediated by the aberrant methylation of the promoter region of DNA is involved in the inactivation of genes implicated in various metabolic pathways. Such a gene hypermethylation has become a useful molecular marker for the diagnosis, treatment and follow-up of cancer patients. Our objective is to analyze the patterns of gene hypermethylation in patients with gynecological tumors.
Patients And Methods:
We selected 115 patients with gynecological cancers: 22 ovarian; 13 endometrial, 11 cervical-uterine and 69 breast cancers. By testing methylation-specific PCR, we studied the methylation status of genes CDNK2A (p16), APC1A, FHIT, CDH1 and hMLH1.
Results:
The frequencies of gene methylation in genes p16, APC1A, FHIT, hMLH1 and CDH1 were 29.2%, 34%, 60.4%, 10.9% and 79.8%, respectively. 70% of cases showed at least two methylated genes, which means a rate of methylation >0.4. The lowest frequency of methylation was seen in ovarian cancer, while the highest one was observed in endometrial cancer.
Conclusions:
The results indicate that the aberrant methylation of the promoter region is an important event in carcinogenesis of gynecological tumors and that the pattern of gene methylation is associated with the nature of the tumor. These particular characteristics can deliver relevant information on the major metabolic pathways altered in each tumor type. In addition to complementary studies (ie, loss of expression and/or function), this represents a clinical tool for the proper management of the disease.
Insights
Aberrant gene promoter hypermethylation is crucial in gynecological tumor development. Methylation patterns vary by tumor type, offering insights into altered metabolic pathways and potential clinical management tools.
Area of Science:
- Molecular biology
- Oncology
- Epigenetics
Context:
- Aberrant DNA promoter hypermethylation drives gene silencing, impacting metabolic pathways.
- Gene hypermethylation serves as a valuable molecular marker for cancer diagnosis, treatment, and monitoring.
- Gynecological tumors exhibit distinct gene methylation profiles.
Purpose:
- To investigate gene promoter hypermethylation patterns in gynecological tumors.
- To analyze the methylation status of specific genes (CDNK2A, APC1A, FHIT, CDH1, hMLH1) in 115 gynecological cancer patients.
- To correlate gene methylation patterns with gynecological tumor types.
Summary:
- Analysis of 115 gynecological cancer patients (ovarian, endometrial, cervical-uterine, breast) revealed varying gene methylation frequencies: CDNK2A (p16) at 29.2%, APC1A at 34%, FHIT at 60.4%, hMLH1 at 10.9%, and CDH1 at 79.8%.
- Approximately 70% of cases displayed methylation in at least two genes.
- Methylation frequencies were lowest in ovarian cancer and highest in endometrial cancer.
Impact:
- Aberrant promoter methylation is a significant factor in gynecological carcinogenesis.
- Distinct gene methylation patterns are associated with specific tumor types, providing insights into altered metabolic pathways.
- These findings support the use of gene methylation analysis as a clinical tool for managing gynecological diseases.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

